WO2002030410A3 - Suppression of cyclin kinase activity for prevention and treatment of infections - Google Patents

Suppression of cyclin kinase activity for prevention and treatment of infections Download PDF

Info

Publication number
WO2002030410A3
WO2002030410A3 PCT/US2001/031835 US0131835W WO0230410A3 WO 2002030410 A3 WO2002030410 A3 WO 2002030410A3 US 0131835 W US0131835 W US 0131835W WO 0230410 A3 WO0230410 A3 WO 0230410A3
Authority
WO
WIPO (PCT)
Prior art keywords
infections
suppression
prevention
treatment
kinase activity
Prior art date
Application number
PCT/US2001/031835
Other languages
French (fr)
Other versions
WO2002030410A2 (en
Inventor
Thomas Albrecht
Laurent Meijer
Priscilla Schaffer
Luis Schang
Original Assignee
Univ Texas
Univ Pennsylvania
Thomas Albrecht
Laurent Meijer
Priscilla Schaffer
Luis Schang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Univ Pennsylvania, Thomas Albrecht, Laurent Meijer, Priscilla Schaffer, Luis Schang filed Critical Univ Texas
Priority to AU2002213132A priority Critical patent/AU2002213132A1/en
Publication of WO2002030410A2 publication Critical patent/WO2002030410A2/en
Publication of WO2002030410A3 publication Critical patent/WO2002030410A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents

Abstract

The present invention relates to methods for use in treating or preventing infections. More particularly, the invention relates to methods for screening for modulators that inhibit cyclin-dependent kinase and the use of these putative inhibitors to control proliferation of a DNA virus that is dependent upon events associated with cell proliferation for replication. The DNA virus includes any of the herpesvirus family, and most particularly human cytomegalovirus.
PCT/US2001/031835 2000-10-10 2001-10-10 Suppression of cyclin kinase activity for prevention and treatment of infections WO2002030410A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002213132A AU2002213132A1 (en) 2000-10-10 2001-10-10 Suppression of cyclin kinase activity for prevention and treatment of infections

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68598600A 2000-10-10 2000-10-10
US09/685,986 2000-10-10
US30418500P 2000-10-11 2000-10-11
US60/304,185 2000-10-11

Publications (2)

Publication Number Publication Date
WO2002030410A2 WO2002030410A2 (en) 2002-04-18
WO2002030410A3 true WO2002030410A3 (en) 2002-07-11

Family

ID=26973864

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/031835 WO2002030410A2 (en) 2000-10-10 2001-10-10 Suppression of cyclin kinase activity for prevention and treatment of infections

Country Status (2)

Country Link
AU (1) AU2002213132A1 (en)
WO (1) WO2002030410A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007016189A2 (en) * 2005-07-28 2007-02-08 University Of Massachusetts Glucose transport-related genes, polypeptides, and methods of use thereof
EP4284335A1 (en) 2021-02-01 2023-12-06 RegenxBio Inc. Gene therapy for neuronal ceroid lipofuscinoses
CN117379432B (en) * 2023-12-12 2024-03-08 北京大学 Application of compound or medicinal salt thereof in preparing medicament for treating and preventing diseases caused by porcine pseudorabies virus

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986002266A1 (en) * 1984-10-12 1986-04-24 United States Of America, Represented By The Unite Use of suramin for clinical treatment of infection with any of the members of the family of human t-cell leukemia (htlv) viruses including lymphadenopathy virus (lav)
WO1990001935A1 (en) * 1988-08-26 1990-03-08 Michel Vandevelde Use of an agent active against retrovirus and products so produced
WO1997016447A1 (en) * 1995-10-31 1997-05-09 Mitotix, Inc. Inhibitors of cyclin-dependent kinases
WO1998039007A1 (en) * 1997-03-03 1998-09-11 Board Of Regents, The University Of Texas System Supression of cyclin kinase 2 activity for prevention and treatment of dna viral infections
WO1999030710A1 (en) * 1997-12-13 1999-06-24 Bristol-Myers Squibb Company USE OF PYRAZOLO [3,4-b] PYRIDINE AS CYCLIN DEPENDENT KINASE INHIBITORS
WO1999062503A2 (en) * 1998-05-29 1999-12-09 Cnrs (Centre National De Recherche Scientifique) France Innovation Scientifique Et Transfert Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases
WO2001037819A2 (en) * 1999-11-23 2001-05-31 Centre National De La Recherche Scientifique (C.N.R.S.) Use of indirubine derivatives for making medicines
FR2804959A1 (en) * 2000-02-15 2001-08-17 Centre Nat Rech Scient USE OF PAULLON DERIVATIVES FOR THE MANUFACTURE OF MEDICAMENTS
WO2001060367A1 (en) * 2000-02-15 2001-08-23 University Of Iowa Research Foundation Compositions comprising flavopiridol and their use for hiv therapy

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986002266A1 (en) * 1984-10-12 1986-04-24 United States Of America, Represented By The Unite Use of suramin for clinical treatment of infection with any of the members of the family of human t-cell leukemia (htlv) viruses including lymphadenopathy virus (lav)
WO1990001935A1 (en) * 1988-08-26 1990-03-08 Michel Vandevelde Use of an agent active against retrovirus and products so produced
WO1997016447A1 (en) * 1995-10-31 1997-05-09 Mitotix, Inc. Inhibitors of cyclin-dependent kinases
WO1998039007A1 (en) * 1997-03-03 1998-09-11 Board Of Regents, The University Of Texas System Supression of cyclin kinase 2 activity for prevention and treatment of dna viral infections
WO1999030710A1 (en) * 1997-12-13 1999-06-24 Bristol-Myers Squibb Company USE OF PYRAZOLO [3,4-b] PYRIDINE AS CYCLIN DEPENDENT KINASE INHIBITORS
WO1999062503A2 (en) * 1998-05-29 1999-12-09 Cnrs (Centre National De Recherche Scientifique) France Innovation Scientifique Et Transfert Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases
WO2001037819A2 (en) * 1999-11-23 2001-05-31 Centre National De La Recherche Scientifique (C.N.R.S.) Use of indirubine derivatives for making medicines
FR2804959A1 (en) * 2000-02-15 2001-08-17 Centre Nat Rech Scient USE OF PAULLON DERIVATIVES FOR THE MANUFACTURE OF MEDICAMENTS
WO2001060367A1 (en) * 2000-02-15 2001-08-23 University Of Iowa Research Foundation Compositions comprising flavopiridol and their use for hiv therapy

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
BRESNAHAN W A ET AL: "INHIBITION OF CELLULAR CDK2 ACTIVITY BLOCKS HUMAN CYTOMEGALOVIRUS REPLICATION", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 231, 1997, pages 239 - 247, XP002922856, ISSN: 0042-6822 *
CHAO S-H ET AL: "FLAVOPIRIDOL INHIBITS P-TEFB AND BLOCKS HIV-1 REPLICATION", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 275, no. 37, 15 September 2000 (2000-09-15), pages 28345 - 28348, XP000986289, ISSN: 0021-9258 *
GRAESER, R. ET AL.: "Plasmodium falciparum protein kinase 5 and the malarial nuclear division cycles", MOLECULAR AND BIOCHEMICAL PARASITOLOGY, vol. 82, no. 1, 12 November 1996 (1996-11-12), pages 37 - 49, XP001069211 *
GRAY N ET AL: "ATP-SITE DIRECTED INHIBITORS OF CYCLIN-DEPENDENT KINASES", CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS BV, BE, vol. 6, no. 9, September 1999 (1999-09-01), pages 859 - 875, XP000856195, ISSN: 0929-8673 *
KITAGAWA, M. ET AL: "A cyclin-dependent kinase inhibitor, butyrolactone I, inhibits phosphorylation of RB protein and cell cycle progression", ONCOGENE, vol. 9, no. 9, September 1994 (1994-09-01), pages 2549 - 2557, XP001069210 *
KNOCKAERT, M. ET AL.: "Intracellular targetsof cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors", CHEMISTRY AND BIOLOGY, vol. 7, no. 6, June 2000 (2000-06-01), UK, pages 411 - 422, XP001070114 *
MEIJER L ET AL: "INHIBITION OF CYCLIN-DEPENDENT KINASES, GSK-3SS AND CK1 BY HYMENIALDISINE, A MARINE SPONGE CONSTITUENT", CHEMISTRY AND BIOLOGY, CURRENT BIOLOGY, LONDON, GB, vol. 7, no. 1, January 2000 (2000-01-01), pages 51 - 63, XP000901413, ISSN: 1074-5521 *
MEIJER L: "CYCLIN-DEPENDENT KINASES INHIBITORS AS POTENTIAL ANTICANCER, ANTINEURODEGENERATIVE, ANTIVIRAL AND ANTIPARASITIC AGENTS", DRUG RESISTANCE UPDATES, CHURCHILL LIVINGSTONE, EDINBURGH, GB, vol. 3, no. 2, 2000, pages 83 - 88, XP000931278, ISSN: 1368-7646 *
SCHANG L M ET AL: "REQUIREMENT FOR CELLULAR CYCLIN-DEPENDENT KINASES IN HERPES SIMPLEXVIRUS REPLICATION AND TRANSCRIPTION", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 72, no. 7, 1998, pages 5626 - 5637, XP000909412, ISSN: 0022-538X *
SHANG, L., M. ET AL.: "Roscovitine, a specific Inhibitor of Cellular Cyclin-Dependent Kinases,, Inhibits Herpes Simplex Virus DNA Synthesis in the presence of Viral Early Proteins", JOURNAL OF VIROLOGY, vol. 74, no. 5, March 2000 (2000-03-01), USA, pages 2107 - 2120, XP001070109 *
SHANG, L., M. ET AL.: "Transcription of Herpes Simplex Virus Immediate-Early and Early Genes Is Inhibited by Roscovitine, an Inhibitor Specific for Cellular Cyclin-Dependent Kinases", JOURNAL OF VIROLOGY, vol. 73, no. 3, March 1999 (1999-03-01), USA, pages 2161 - 2172, XP001070110 *
VEERANNA ET AL.: "Inhibition of Neuronal Cyclin-Dependent Kinase-5 by Staurosporine and Purine Analogs is Independent of Activation by Munc-18", NEUROCHEMICAL RESEARCH, vol. 21, no. 5, May 1996 (1996-05-01), pages 629 - 636, XP001069208 *
WATERS N.C. ET AL.: "Cyclin H activation and drug susceptibility of the Pfmrk cyclin dependent protein kinase from Plasmodium falciparum", MOLECULAR AND BIOCHEMICAL PARASITOLOGY, vol. 107, 2000, pages 45 - 55, XP001069206 *

Also Published As

Publication number Publication date
AU2002213132A1 (en) 2002-04-22
WO2002030410A2 (en) 2002-04-18

Similar Documents

Publication Publication Date Title
AU2003274071A1 (en) Dosage form that is safeguarded from abuse
AU2001247331A1 (en) Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
AU6276194A (en) Use of monoterpenes, sesquiterpernes and diterpernes for the treatment of cancer
AU6174900A (en) Use of flavones, coumarins and related compounds to treat infections
CL2004001174A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING: 1- (4-FLUOROPHENYL) -3 (R) - [3- (4-FLUOROPHENYL) -3 (S) -HYDROXIPROPIL] -4 (S) - (4-HYDROXIFENYL) -2-ACETIDINONE ( EZETIMIBA) AND EXCIPIENTS; AND ITS USE IN THE TREATMENT AND / OR PREVENTION OF ATEROSCLEROSIS, HIPERCOLESTEROLEMIA, DAY
PL325956A1 (en) Application of 2-amino-4-(4-fluorobenzylamino)-1-ethoxycarbonylaminobenzene in prophylaxis and treatment of the effects of encephalitis and chronic encephalaemia as well as degenerative nervous system affections
NO985856L (en) Absorbent objects that breathe and have odor control
PL323490A1 (en) Tetralinic compounds exibiting acitity against multgiple-drug refractoriness
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
EP1003519A4 (en) Supression of cyclin kinase 2 activity for prevention and treatment of dna viral infections
DE60132851D1 (en) Medicines for the prevention, alleviation or treatment of hypertension
WO2003053360A3 (en) Treatment of ebv and khsv infection and associated abnormal cellular proliferation
WO2002030410A3 (en) Suppression of cyclin kinase activity for prevention and treatment of infections
AU4376396A (en) Use of andrographolide compounds to treat or prevent pathogenicity of diseases
HUP0203682A2 (en) Method for administering a phosphodiesterase 4 inhibitor
AUPQ622600A0 (en) Treatment and/or prevention of ocular pain
WO2001021647A3 (en) Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases
AU2002304710A1 (en) Mrp8/mrp14 heterodimer, or its individual components in combination, for treating and/or preventing skin diseases, wounds and/or wound-healing disturbances
CA2270423A1 (en) Prophylactic/therapeutic agent
WO1996002240A3 (en) Use of inhibitors of human s-cd23
AU2001269082A1 (en) Use of phyllanthus constituents for treating or preventing infections caused by flaviviridae
MX9601149A (en) Use of a calcitonine gene-derived peptide antagonist for the treatment of pruritus and ocular and palpebral dysaesthesias, and composition including said antagonist.
WO2003015689A3 (en) Pharmaceutical composition for the prophylaxis and/or treatment of virus diseases
HUP0302738A3 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
HK1061209A1 (en) Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)